Toxic epidermal necrolysis treated with human gamma globulin
Main Article Content
Keywords
PubMed, MeSH, Clinical research
Abstract
In the process of responding to questions generated during medical care, the number of articles appearing in the search is so vast that a strategy must be considered. This article describes the process to find and select the information to help us respond the needs of our patients. The judgment of the quality and relevance of the answer depends on each reader. Initially you have to look in places where there is medical arbitration for publications, reasons why we recommend PubMed. Start the search once the acronym PICO breakdown, where P is for patients, I intervention, C comparator and O outcome or result; these words are used as MeSH (Medical Subject Headings) and are linked with boolean terms (and, or and not). The acronym PICO shares components with the classical model of the Architecture of the Research described by Dr. Alvan R. Feinstein. A good search should participate in the response to our question in the first 20 articles, if it does not happen, the search must be more specific with the use of filters.
References
Wanat KA, Anadkat MJ, Klekotka PA. Seasonal variation of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with trimethoprim-sulfamethoxazole. J Am Acad Dermatol 2009;60(4):589-594.
Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003;139(1):26-32.
Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129(1):92-96.
Ringheanu M. Toxic epidermal necrolysis in children. An update. Clin Pediatr 2000;39(12):687.
Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol 2007;56(2):181-200.
Murata J, Abe R, Shimizu H. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. J Allergy Clin Immunol 2008;122(5):992-1000.
Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003;139(1):33-36. Disponible en http://archderm.ama-assn.org/cgi/content/full/139/1/33
Prins C, Gelfand EW, French LE. Intravenous immuno-globulin: properties, mode of action and practical use in dermatology. Acta Derm Venereol 2007;87(3):206-218. Disponible en http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-0249
Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003;139(1):26-32.
Trent JT, Fangchao M, Kerdel F, Fie S, French LE, Roma-nelli P, Kirsner RS. Dose of intravenous immunoglobulin and patient survival in SJS and toxic epidermal necrolysis. Expert Rev Dermatol 2007;2(3):299-303.
Khalili B, Bahna SL. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol 2006;97(3):272-280.